Natixis Advisors, L.P. Argenx Se Transaction History
Natixis Advisors, L.P.
- $68.5 Billion
- Q3 2025
A detailed history of Natixis Advisors, L.P. transactions in Argenx Se stock. As of the latest transaction made, Natixis Advisors, L.P. holds 24,503 shares of ARGX stock, worth $22.2 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
24,503
Previous 19,070
28.49%
Holding current value
$22.2 Million
Previous $10.5 Million
71.92%
% of portfolio
0.03%
Previous 0.02%
Shares
10 transactions
Others Institutions Holding ARGX
# of Institutions
526Shares Held
26MCall Options Held
589KPut Options Held
320K-
Price T Rowe Associates Inc Baltimore, MD3.64MShares$3.31 Billion0.29% of portfolio
-
Janus Henderson Group PLC London, X02.58MShares$2.34 Billion0.92% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI2.19MShares$1.99 Billion2.46% of portfolio
-
Capital World Investors Los Angeles, CA1.96MShares$1.78 Billion0.21% of portfolio
-
Black Rock Inc. New York, NY1.01MShares$918 Million0.01% of portfolio
About ARGENX SE
- Ticker ARGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,323,800
- Market Cap $50.2B
- Description
- argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...